# A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

> clinical trial · VERIFIED · 2026-08-26

Status: ACTIVE_NOT_RECRUITING · Sponsor: Eli Lilly and Company · Condition: Alzheimer Disease

- Company: Eli Lilly and Company
- Sector: biotech
- Primary source: https://clinicaltrials.gov/study/NCT04437511

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.